Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq
Rhea-AI Filing Summary
Humacyte, Inc. (HUMA) has had its Redeemable Warrants removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. These warrants were each exercisable for one share of common stock at an exercise price of $11.50. Nasdaq states that it has complied with its own rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing, and that Humacyte has complied with the Exchange’s rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal. Nasdaq, through an authorized officer, certifies that it has reasonable grounds to believe it meets all requirements for filing Form 25.
Positive
- None.
Negative
- None.
Key Figures
Warrant exercise price: $11.50 per share
Exchange Act section: Section 12(b)
CFR rule subsection (b): 17 CFR 240.12d2-2(b)
+1 more
4 metrics
Warrant exercise price
$11.50 per share
Each redeemable warrant exercisable for one share of common stock
Exchange Act section
Section 12(b)
Basis for removal from listing and/or registration
CFR rule subsection (b)
17 CFR 240.12d2-2(b)
Exchange compliance to strike class from listing
CFR rule subsection (c)
17 CFR 240.12d2-2(c)
Issuer compliance for voluntary withdrawal from listing
Key Terms
Form 25, Section 12(b), Redeemable Warrants, 17 CFR 240.12d2-2
4 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) regulatory
"under SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
Redeemable Warrants financial
"Redeemable Warrants, each whole warrant exercisable for one share"
A redeemable warrant is a tradable right that lets its holder buy a company’s shares at a fixed price before a set date, but the issuer has the contract power to cancel (redeem) the warrant early under agreed terms. For investors this matters because early redemption can force decision-making, change the timing of when new shares might be created, and affect potential gains or dilution—much like a store coupon that the issuer can cancel by paying you off instead of letting you use it.
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
FAQ
What security of Humacyte, Inc. (HUMA) is affected by this Form 25 filing?
The filing covers Humacyte’s Redeemable Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50, which are being removed from listing and/or registration on the Nasdaq Stock Market LLC.
Is Humacyte, Inc. (HUMA) voluntarily withdrawing its warrants from Nasdaq?
The document states that, under 17 CFR 240.12d2-2(c), Humacyte has complied with the Exchange’s rules and the requirements governing the voluntary withdrawal of this class of securities from listing and registration on Nasdaq.
What regulatory basis is cited for removing Humacyte (HUMA) warrants from listing?
The removal is made under Section 12(b) of the Securities Exchange Act of 1934 and 17 CFR 240.12d2-2(b) and (c), which govern the striking of a class of securities from listing and the voluntary withdrawal of such securities.
What is the exercise price of Humacyte (HUMA) redeemable warrants being delisted?
Each redeemable warrant was exercisable for one share of Humacyte common stock at an exercise price of $11.50 per share, as stated in the description of the class of securities affected by this Form 25.
AI-generated analysis. How Rhea-AI works. Not financial advice.
